DOI: https://doi.org/10.22263/2312-4156.2020.6.20
Volkava M.V.1, Kundzer A.V.1, Konevalova N.Y.2, Frolova A.V.2
Rheumatoid arthritis: socio-economic significance and modern approaches to the immunopathogenetic treatment
1Belarusian Medical Academy of Post-Graduate Education, Minsk, Republic of Belarus
2Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2020;19(6):20-30.
Abstract.
Rheumatoid arthritis (RA) is the most common and severe chronic autoimmune disease. RA is characterized by a negative impact on the duration and quality of life, work activity of the patients, and significant material costs of the health care system. Early detection and treatment for RA is important to reduce the negative consequences of the disease. With this purpose new classification criteria have been developed that make it possible to diagnose RA at an early stage, and a clear therapeutic strategy «treatment to the goal» has been formulated. This review summarizes current information about the prevalence and socio-economic significance of RA. Principles of the international law concerning the treatment of the disease and the definition of concepts related to biological therapy of RA are given. The main biologics used for the treatment of RA in the Republic of Belarus are characterized.
Key words: rheumatoid arthritis, prevalence, socio-economic significance, treatment, biological therapy, biologics.
References
1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: http://dx.doi.org/10.1002/art.27584
2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: http://dx.doi.org/10.1136/annrheumdis-2015-207524
3. Krishnan E, Lingala B, Bruce B, Fries JF. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012;71(2):213-8. doi: http://dx.doi.org/10.1136/annrheumdis-2011-200354
4. Batko B, Rolska-Wójcik P, Władysiuk M. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment – A Systematic Literature Review. Int J Environ Res Public Health. 2019;16. Available from: https://www.mdpi.com/1660-4601/16/16/2966 [Accessed 27th November 2020].
5. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019 Nov;78(11):1463-1471. doi: http://dx.doi.org/10.1136/annrheumdis-2019-215920
6. Lila AM, Dreval RO, Shipitcyn VV. Assessment of the organization of medical care and drug provision for rheumatic diseases and the socio-economic burden of these diseases in the Russian Federation. Sovremen Revmatologiia. 2018;12(3):112-9. (In Russ.)
7. Folomeeva OM, Nasonov EL, Andrianova IA, Galushko EA, Goryachev DV, Dubinina TV, i dr. Rheumatoid arthritis in rheumatological practice in Russia: the severity of the disease in the Russian population of patients. Cross-sectional Epidemiological Study (Raiser). Nauch-Prakt Revmatologiia. 2010;48(1):50-60. (In Russ.)
8. Volkova MV, Kunder EV. Early arthritis: relevance, immunopathology, diagnosis. Vestn VGMU. 2013;12(3):13-24. (In Russ.)
9. Abhishek A, Nakafero G, Kuo C-F, Mallen C, Zhang W, Grainge MJ, et al. Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink. Rheumatology (Oxford). 2018 Jun;57(6):977-981. doi: http://dx.doi.org/10.1093/rheumatology/key013
10. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. Associations of disease activity and treatment with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford). 2011 Jan;50(1):101-9. doi: http://dx.doi.org/10.1093/rheumatology/keq232
11. Pedersen JK, Holst R, Primdahl J, Svendsen AJ, Hørslev-Petersen K. Mortality and its predictors in patients with rheumatoid arthritis: a Danish population-based inception cohort study. Scand J Rheumatol. 2018 Sep;47(5):371-377. doi: http://dx.doi.org/10.1080/03009742.2017.1420223
12. Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1756-1763. doi: http://dx.doi.org/10.1002/acr.23567
13. Meyer PW, Anderson R, Ker JA, Ally MT. Rheumatoid arthritis and risk of cardiovascular disease. Cardiovasc J Afr. 2018 Sep-Oct;29(5):317-321. doi: http://dx.doi.org/10.5830/CVJA-2018-018
14. Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019 Aug;3. Available from: https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-019-0080-9 [Accessed 27th November 2020].
15. Karateev DE. Main trends and variability in the evolution of rheumatoid arthritis: results of long-term follow-up. Nauch-Prakt Revmatologiia. 2004;42(1): 8-14. (In Russ.)
16. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum. 2000 Sep;43(9):1927-40. doi: http://dx.doi.org/10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B
17. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017 Mar;19. Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1266-4 [Accessed 27th November 2020].
18. Nasonov EL. Rheumatoid Arthritis: Therapeutic Challenges. Vrach. 1999;(5):7-10. (In Russ.)
19. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados Maxime, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: http://dx.doi.org/10.1136/annrheumdis-2019-216655
20. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep;65(9):1175-83. doi: http://dx.doi.org/10.1136/ard.2005.046367
21. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010 Jan;26(1):77-90. doi: http://dx.doi.org/10.1185/03007990903422307
22. Lila AM, Dreval' RO, Shipitsyn VV. Assessment of the organization of medical care and drug provision for rheumatic diseases and the socio-economic burden of these diseases in the Russian Federation. Sovrem Revmatologiia. 2018;12(3):112-9. (In Russ.)
23. Volkova MV. Predicting the effectiveness of infliximab in rheumatoid arthritis. Lecheb Delo. 2019;(5):17-21. (In Russ.)
24. Lorenz HM. Biological agents: a novel approach to the therapy of rheumatoid arthritis. Expert Opin Investig Drugs. 2000 Jul;9(7):1479-90. doi: http://dx.doi.org/10.1517/13543784.9.7.1479
25. Nasonov EL, Nasonova VA, red. Rheumatology: nats ruk. 2-e izd, ispr i dop. Moscow, RF: GEOTAR-Media; 2010. 720 р.
26. Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, Feldmann M. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I56-60. doi: http://dx.doi.org/10.1136/ard.58.2008.i56
27. Instructions for use of the drug Remicade. V: Vidal Belarus’. Spravochnik lekarstvennykh preparatov [Elektronnyi resurs]. Rezhim dostupa: https://www.vidal.by/poisk_preparatov/remicade.html. Data dostupa: 02.12.2020. (In Russ.)
28. Kobayashi D, Ito S, Takai C, Hasegawa E, Nomura Y, Otani H, et al. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2018 Jul;28(4):599-605. doi: http://dx.doi.org/10.1080/14397595.2017.1380250
29. Adalimumab (Adalimumab). V: Vidal. Spravochnik lekarstvennykh sredstv [Elektronnyi resurs]. Rezhim dostupa: https://www.vidal.ru/drugs/molecule/1785. Data dostupa: 27.11.2020.
30. Nasonov EL. Etanercept: results and prospects of use in rheumatoid arthritis. Nauch-Prakt Revmatologiia. 2012;(4 Pril 4):2-21. (In Russ.)
31. Juhász P, Mester Á, Biró A-J, Héjj G, Poór G. Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study. BMC Musculoskelet Disord. 2014 Jul;15. Available from: https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-15-251 [Accessed 27th November 2020].
32. Aaltonen KJ, Ylikylä S, Joensuu JT, Isomäki P, Pirilä L, Kauppi M, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017 May;56(5):725-735. doi: http://dx.doi.org/10.1093/rheumatology/kew467
33. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J Rheum Dis. 2018 May;21(5):922-9.
34. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016 Apr;20(35):601-10. doi: http://dx.doi.org/10.3310/hta20350
35. Ceccarelli F, Massafra U, Perricone C, Idolazzi L, Giacomelli R, Tirri R, et al. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE). Clin Exp Rheumatol. 2017 Jan-Feb;35(1):24-32.
36. Siljehult F, Ärlestig L, Eriksson C, Rantapää-Dahlqvist S. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 Sep;47(5):345-350. doi: http://dx.doi.org/10.1080/03009742.2018.1433232
37. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26. doi: http://dx.doi.org/10.1038/ncprheum0338
38. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011 Jan;38(1):10-20. doi: http://dx.doi.org/10.3899/jrheum.100717
39. Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, et al. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group. Mod Rheumatol. 2016 Nov;26(6):828-835. doi: http://dx.doi.org/10.3109/14397595.2016.1160991
40. Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol. 2017 Jan;36(1):25-34. doi: http://dx.doi.org/10.1007/s10067-016-3435-2
41. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 May;381(9877):1541-50. doi: http://dx.doi.org/10.1016/S0140-6736(13)60250-0
42. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016 Nov;75(11):1917-1923. doi: http://dx.doi.org/10.1136/annrheumdis-2015-208426
43. Paul SK, Montvida O, Best J, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and nonbiologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data. Semin Arthritis Rheum. 2018 Feb;47(4):478-484. doi: http://dx.doi.org/10.1016/j.semarthrit.2017.08.001
44. Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis. Int J Mol Sci. 2019 Sep;20(18):4633. doi: http://dx.doi.org/10.3390/ijms20184633
45. Kim SC, Schneeweiss S. When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and its Cardiovascular Safety. Arthritis Rheumatol. 2020 Jan;72(1):4-6. doi: http://dx.doi.org/10.1002/art.41092
46. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010 Dec;5(12):e14328. doi: http://dx.doi.org/10.1371/journal.pone.0014328
47. Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int. 2013 Mar;33(3):697-703. doi: http://dx.doi.org/10.1007/s00296-012-2375-7
48. Gossec L, Steinberg G, Rouanet S, Combe B. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study. Clin Exp Rheumatol. 2015 Sep-Oct;33(5):664-70.
49. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2018 Dec;13:57-70. doi: http://dx.doi.org/10.2147/DDDT.S150580
50. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629-35. doi: http://dx.doi.org/10.1136/ard.2009.119933
51. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun;350(25):2572-81. doi: http://dx.doi.org/10.1056/NEJMoa032534
52. Williams JH, Hutmacher MM, Zierhut ML, Becker J-C, Gumbiner B, Spencer-Green George, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a рroposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579. doi: http://dx.doi.org/10.1111/bcp.13094
53. Nasonov EL, Zonova EV, Ivanova ON, Knyazeva LA, Mazurov VI, Samigullina RR, i dr. Results of a Phase III Comparative Clinical Study of Rituximab (Acellbia® and Mabthera®) for Rheumatoid Arthritis (Biora Study). Nauch-Prakt Revmatologiia. 2016;54(5):510-9. (In Russ.)
54. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013 Mar;72(3):329-36. doi: http://dx.doi.org/10.1136/annrheumdis-2011-201117
55. Qianwen L, Yufeng Y, Xin L, Guangliang S, Xiangni W, Di L, Yongzhe L, Xuan Z. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One. 2014 Feb;9(2):e89442. doi: http://dx.doi.org/10.1371/journal.pone.0089442
56. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 Jul;388(10041):239-47. doi: http://dx.doi.org/10.1016/S0140-6736(16)00380-9
57. Santos-Faria D, Tavares-Costa J, Eusébio M, Silva JL, Rodrigues JR, Sousa-Neves J, et al. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. Acta Reumatol Port. 2019 Apr-Jun;44(2):103-113.
58. Coffey CM, Richter MD, Crowson CS, Koster MJ, Warrington KJ, Ytterberg SR, et al. Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events. J Rheumatol. 2020 Apr;47(4):518-523. doi: http://dx.doi.org/10.3899/jrheum.181397
59. Duarte AC, Porter JC, Leandro MJ. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology (Oxford). 2019 Nov;58(11):2031-2038. doi: http://dx.doi.org/10.1093/rheumatology/kez177
60. Iaccheri B, Androudi S, Bocci Bartoloni E, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. cul Immunol Inflamm. 2010 Jun;18(3):223-5. doi: http://dx.doi.org/10.3109/09273941003739928
61. Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty’s syndrome. Am J Ther. 2008Jul-Aug;15(4):321-2. doi: http://dx.doi.org/10.1097/MJT.0b013e318164bf32
62. Zisapel M, Paran D, Elkayam O. Rituximab in rheumatoid arthritis - therapeutic aspects based on 18 years of global experience. Harefuah. 2019 Sep;158(9):595-600.
Information about authors:
Volkava M.V. – Candidate of Medical Sciences, associate professor of the Chair of Cardiology & Rheumatology, Belarusian Medical Academy of Post-Graduate Education;
Kundzer A.V. – Doctor of Medical Sciences, professor of the Chair of Cardiology & Rheumatology, Belarusian Medical Academy of Post-Graduate Education;
Konevalova N.Y. – Doctor of Biological Sciences, professor of the Chair of General & Clinical Biochemistry with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Frolova A.V. – Doctor of Biological Sciences, professor of the Chair of Clinical Microbiology, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 220013, Minsk, 3-3 P. Brovki str., Belarusian Medical Academy of Post-Graduate Education, Chair of Cardiology & Rheumatology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Marharyta V. Volkava.
